ClinicalTrials.Veeva

Menu

Palliative Care for Persons With ADRD and CI in SNF

University of Maryland Baltimore (UMB) logo

University of Maryland Baltimore (UMB)

Status

Completed

Conditions

Cognitive Impairment
Advance Care Planning
Skilled Nursing Facility
Palliative Care

Treatments

Other: Palliative Care Consultation

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT05308004
3K23NR017663-02S1 (U.S. NIH Grant/Contract)
1K23NR017663-01A1 (U.S. NIH Grant/Contract)
HP-00100348

Details and patient eligibility

About

Alzheimer's disease and related dementias (ADRD) are serious, life limiting illnesses with no known cure. Dementia is the fifth-leading cause of death in older adults and the majority of people with advanced dementia die in nursing homes (NHs). Miller et al reported that 40% of U.S. NH residents dying with advanced dementia received Skilled Nursing Facility (SNF) care in the last 90 days of life, and receipt of this care was associated significantly with poorer end-of-life outcomes, including a higher risk of dying in a hospital, compared to decedents with no SNF care. SNF care is a Medicare post-acute rehabilitation service delivered in NHs focused on intense rehabilitation and/or aggressive, disease-modifying therapies. Regardless of life expectancy, use of SNF care precludes access to Hospice services. Palliative care (PC) offers an evidence-based alternative.

Full description

In this pragmatic clinical trial, broadcast notification will be utilized to inform all newly admitted patients at each study site of their participation in this trial. During the admission process, potential subjects will be provided with a 1-page summary sheet (Broadcast notification) detailing their participation in this study that will include contact information for the study team, should the subject or their LAR/surrogate decision maker elect to opt-out of participating.

Baseline data will be collected virtually via telephone by asking each subject or if unable to respond their surrogate decision maker to complete the Patient Outcomes Scale (POSv2), the Satisfaction With Care at the End of Life in Dementia (SWC-EOLD), and the Symptom Management at the End of Life in Dementia (SM-EOLD).

Between 14 days and 21 days after the baseline POSv2, SW-EOLD, and the SM-EOLD are administered, all subjects or if unable to respond their surrogate decision maker will be asked to complete the POSv2, SW-EOLD, and the SM-EOLD again virtually via telephone. The POSv2, SW-EOLD, and the SM-EOLD will be given a total of two times to those in the INTERVENTION and CONTROL groups; at baseline and follow up (14-21 days later).

Deidentified subject demographics will be collected on all participants in the following way: Study team members will review subject's medical records and enter de-identified data into a Research Electronic Data Capture (REDCap) database (Acts staff assists with the study team's access to subject's medical record).

Palliative Care Encounter Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering.

Enrollment

7 patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

KEY INCLUSION CRITERIA

Patients:

  • Admitted for SNF post-acute care at a participating NHs following a recent hospitalization
  • Age ≥ 60 years old
  • Speaks English (if verbal)
  • If non-verbal/unable to participate in a conversation and/or unable to make decisions, a legally authorized representative (LAR)/surrogate decision maker who can make decisions for the patient as determined by ACTs staff
  • Documented ADRD diagnosis in the medical record or history of cognitive impairment (defined as BIMS score ≤ 12)
  • At least one global indicator for PC at SNF admission (provider would not be surprised if patient died within 1 year, believes the patient would benefit from advance care planning or symptom management; frequent hospital or NH SNF admissions; complex care requirements; decline in function; feeding intolerance; unintended decline in weight; or previous hospice assessment or enrollment and subsequent discharge)

Surrogate/LAR:

  • ≥18 years old
  • Family member or friend of an eligible patient as determined by ACTs staff
  • Speaks English

KEY EXCLUSION CRITERIA

Patients:

  • Who have previously received or are referred for PC by their primary care team
  • With a discharge plan within 48 hours of screening
  • Currently receiving hospice care
  • Who do not have one global indicator of need
  • No documented ADRD diagnosis or history of cognitive impairment in the medical record
  • That are non-English speaking, (if verbal)
  • If unable to make decisions, do not have an LAR/surrogate decision maker.

Surrogate/LAR:

  • < 18 years of age
  • Not a family Member or friend of an eligible patient
  • Non-English speaking

Trial design

Primary purpose

Supportive Care

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

7 participants in 2 patient groups

Standard Care
No Intervention group
Description:
Participants will receive the standard Medicare Skilled Nursing Facility care.
Palliative Care Consult
Experimental group
Description:
Participants will receive the standard Medicare Skilled Nursing Facility care plus a Palliative Care Consultation with a trained provider.
Treatment:
Other: Palliative Care Consultation

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems